Type/Product Area

Terms/Details (Date)

First Genetic Trust Inc.*

nTouch Research Corp.*

Alliance to advance the discovery and development of a new generation of pharmaceutical products matched to individual patients' genetic makeup

First Genetic's information technology operating system for genomic research and molecular medicine will be integrated with nTouch Research's biorepository of DNA samples (4/5)

Genomics Collaborative Inc.*

AnVil Informatics Inc.*

Agreement to apply AnVil's analysis and visualization knowledge and tools to GCI's DNA microarray data

The project is designed to develop integrated visual analytic systems to identify gene expression patterns (4/24)

Glaucus Proteomics BV* (the Netherlands)

SARA and GigaPort* (the Netherlands)

Agreements to provide the biocomputing capacity and connectivity to help Glaucus with the development of tools and technologies

The tools and technologies will be for high-throughput proteomic analysis and the screening of antibody and small-molecule drug candidates for improved specificity (4/24)

Matritech Inc. (NMPS)

Bruker Daltonics Inc. (BDAL)

Partnership to develop an automated mass spectrometer system

The system would allow clinical laboratories to perform Matritech's proteomics-based cancer tests, including blood tests for breast and prostate cancer (5/20)

Paracel Inc. (unit of Celera Genomics Group; NYSE:CRA)

Sun Microsystems Inc. (SUNW)

Paracel Transcript-Assembler and Paracel Genome-Assembler software

Agreement is to market the software on Sun platforms (3/12)

Senomyx Inc.*

Nestle SA (Switzerland; Neuer Markt:NESZ)

Collaborative research and license agreement to discover and commercialize new ingredients to enhance taste of specified consumer food products

Nestle will provide research funding over a three-year period, as well as potential milestone payments and royalties (5/6)

Senomyx Inc.*

The Coca-Cola Co. (NYSE:KO)

Agreement to research new flavors of soft drinks and other nonalcoholic beverages

Coca-Cola will pay Senomyx to conduct research and development in the field of flavor discovery; Senomyx must reach specific research goals and would receive royalties from the sale of any product that might use flavors it develops (5/7)

Tensor Biosciences*

Matsushita Electric Industrial Co. Ltd. (Japan; NYSE:MC)

Five-year agreement to develop Brain-on-a-Chip drug discovery technology

The Brain-on-a-Chip platform is centered around the MED64 system developed by Matsushita; the drug-testing assays developed by Tensor will be patented by Matsushita and licensed exclusively back to Tensor for drug discovery (5/7)


# This chart does not include agreements that involve agricultural product development; chart includes one item before March 26 that was not listed in previous chart.

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market.

NYSE = New York Stock Exchange

No Comments